Psychotropic medication in adults with mental retardation: prevalence, and prescription practices
Introduction
Psychotropic medication is a common approach to dealing with psychiatric disorders and problem behaviour in people with mental retardation. Studies some years ago showed that 30–75% of the people with mental retardation living in institutions in the US had been prescribed psychotropics (Aman & Singh, 1988; Martin & Agran, 1985; Stone, Alvarez, Ellman, Hom & White, 1989). More recently, studies conducted in both community and institutional settings show that about 35–40% are using psychotropics (Pyles, Muniz, Cade & Silva, 1997; Rinck, 1998). People with mental retardation comprise perhaps the most overmedicated population we have (Matson et al., 2000; Reiss & Aman, 1997).
A common assumption is that medications which are successful in the treatment of psychiatric disorders in persons without mental retardation are equally successful in treating the same disorders in persons with mental retardation (Sevin, Bowers-Stephens, Hamilton & Ford, 2001). Consequently, the likelihood of effective treatment should increase with precise diagnoses. However, diagnosing might be a difficult task in itself, especially in people with severe and profound mental retardation, although diagnostic instruments have been improved in recent years (Sturmey, 1995).
An important question becomes how well treatment efficacy is documented. After a thorough review of the literature, Sevin et al. (2001) concluded that there “is at least moderate support for the efficacy of psychotropic medications in treating some types of psychopathology in persons with mental retardation” (p. 464). Efficacy of psychotropic medication on problem behaviours like self-injury, stereotypies, physical aggression, overactivity, destructiveness, and disruptive behaviour, has also been investigated (Matson et al., 2000). Generally speaking, some efficacy seems to be documented. However, most studies of psychotropic treatment of psychiatric disorders and problem behaviours in people with mental retardation have severe methodological flaws (Matson et al., 2000). Typical ones are lack of behavioural assessment and treatment prior to medications, e.g. in order to see whether medications are necessary at all, or can be combined with behavioural interventions. Others are changes in treatment during the course of the study, and lack of objective measurements and clearly defined dependent variables. Although psychotropics have a place in the treatment of psychiatric disorders and behaviour problems in people with mental retardation, the scientific basis for prescribing psychotropics to persons with mental retardation must be said to be insufficiently established.
Although efficacy is limited, psychiatric disorders and problem behaviours are frequently managed by medication alone. There is some consensus that psychotropics are overused, i.e. used more than what is justified by treatment efficacy (Baumeister & Sevin, 1990; Reiss & Aman, 1997). Studies indicate that a peer review process with a psychiatrist may reduce the use of psychotropics in this population by as much as 50%, without any adverse effects upon the person’s psychiatric illness or problem behaviour (Molyneux, Emerson & Caine, 1999). More specifically, studies have also demonstrated successful withdrawal of neuroleptics in many cases (Ahmed et al., 2000, Branford, 1996).
A significant proportion, one study indicate 20% (Aman & Singh, 1988), even show adverse reactions to psychotropics. Examples are exacerbation of self-injurious behaviour, agitation, aggression, onset of psychosis and depression, and negative effects on learning (Aman & Singh, 1988; Pyles et al., 1997). Moreover, medications are sometimes prescribed without a psychiatric diagnosis, or for behaviours not scientifically demonstrated to be influenced by them (Schaal & Hackenberg, 1994). Suppression of problem behaviours through sedation is only recommended as a last resort, and not for long periods (Matson, Bielecki, Mayville & Matson, 2003; Pyles et al., 1997). Another matter of concern is polypharmacy, i.e. prescribing more than one medication in order to treat the same symptoms (Sturmey, 1999).
Yet another reason for talking about overuse of psychotropics is that many behaviour problems in people with mental retardation are influenced by learning and environmental factors, and that a lot of behaviour problems can be treated by behavioural approaches (Campbell, 2003), alone or in combination with psychotropic medication (Sevin et al., 2001). However, behavioural treatment can be hard to implement, because it sometimes requires extensive staff training, and may be expensive and labour intensive (Matson et al., 2003). Lack of behavioural expertise is another possible limitation. Consequently, medication may be preferred to behavioural approaches.
Due to limited efficacy and possible side effects, and the possibility of therapeutic alternatives, caution should be exercised when psychotropics are used in the treatment of people with mental retardation. Current guidelines include psychiatric assessments, accurate behavioural definitions, assessments of learning and environmental factors, and consideration of behavioural treatment, prior to medication. Guidelines also emphasize systematic evaluation of effects, both when the target is psychiatric symptoms and problem behaviour, and systematic evaluation of side effects (see Kalachnik et al., 1998, Pyles et al., 1997). The aim of the following study was to investigate the prevalence of use of psychotropics in people with mental retardation living in a county of Norway, and to what extent prescription guidelines were fulfilled.
Section snippets
Sampling of participants
Participants (n = 300) were drawn from people with administratively defined mental retardation, i.e. persons with mental retardation receiving at least a minimum of services from health or educational authorities. All participants were more than 18 years old, and were living in community settings in the county of Hedmark, Norway. Local supervisors, with access to information about all people meeting the above definition within their districts, agreed to select a specified number of participants
Sample details
Age distribution of the total sample was: 18–30 years, 17.7% (n = 52); 31–45 years, 30.6% (n = 90); <46 years, 51.7% (n = 152). There were 52.9% males (n = 153) and 47.1% females (n = 136) in the total sample. 17.7% of the participants (n = 52) had mild; 48.3% (n = 142) moderate; 23.8% (n = 70) severe; and 10.2% (n = 30) profound mental retardation.
Prevalence of psychotropic medication
One-hundred ten participants (37.4%) used psychotropic medication. 25.9% (n = 76) used one medication, 9.2% (n = 27) used two, and 2.4% (n = 7) used
Discussion
A principal finding of this study was that as many as 37% of people with administratively defined mental retardation used psychotropic medication. Neuroleptics were the most widely used, followed by antidepressants and anticonvulsants. Other categories were more modestly represented. The use of traditional neuroleptics was extensive, compared with second generation neuroleptics. People using medication were older than people not using medication. Additionally, medications, particularly
References (21)
- et al.
Pharmacologic control of aberrant behavior in the mentally retarded: Toward a more rational approach
Neuroscience and Biobehavioral Reviews
(1990) Efficacy of behavioral interventions for reducing problem behavior in persons with autism: A quantitative synthesis of single-subject research
Research in Developmental Disabilities
(2003)- et al.
Psychotropic and anticonvulsant drug use by mentally retarded adults across community residential and vocational placements
Applied Research in Mental Retardation
(1985) - et al.
Psychopharmacology and mental retardation: A ten-year review (1990–1999)
Research in Developmental Disabilities
(2000) - et al.
Psychopharmacology research for individuals with mental retardation: Methodological issues and suggestions
Research in Developmental Disabilities
(2003) - et al.
A behavioral diagnostic paradigm for integrating behavior-analytic and psychopharmacological interventions for people with a dual diagnosis
Research in Developmental Disabilities
(1997) - et al.
Integrating behavioral and pharmacological interventions in treating clients with psychiatric disorders and mental retardation
Research in Developmental Disabilities
(2001) Diagnostic-based pharmacological treatment of behavior disorders in persons with developmental disabilities: A review and a decision-making typology
Research in Developmental Disabilities
(1995)- et al.
Reducing antipsychotic medication in people with a learning disability
British Journal of Psychiatry
(2000) - Aman, M. G., & Singh, N. N. (1988). Psychopharmacology of the developmental disabilities. Berlin:...
Cited by (98)
Pharmacological treatment for challenging behavior in adults with intellectual disability: Systematic review and meta-analysis
2023, Revista de Psiquiatria y Salud MentalFactors associated with use of medication for behavioral challenges in adults with intellectual and developmental disability
2022, Research in Developmental DisabilitiesUse of antipsychotics, benzodiazepine derivatives, and dementia medication among older people with intellectual disability and/or autism spectrum disorder and dementia
2017, Research in Developmental DisabilitiesCitation Excerpt :It is, however, noteworthy that the yearly percentage of prescription of antipsychotics is fairly stable at 35%, and that there seems to be a lag in prescription of dementia treatment following the diagnosis of dementia. The yearly antipsychotic prescription rate of 35% is in line with rates found in a Norwegian study including adults with administratively defined ID living in community settings (Holden & Gitlesen, 2004), as well as a study reviewing medical records of people with ID in residential settings in the Netherlands (de Kuijper et al., 2010). It is, however, higher than what was found in group homes in the Netherlands (Stolker, Koedoot, Heerdink, Leufkens, & Nolen, 2002), among adults in a community setting in Australia (Doan et al., 2013), and in a primary health care setting in the U.K. (Molyneux, Emerson, & Caine, 1999) and Catalonia (Rubio-Valera et al., 2012).
Reduction or discontinuation of antipsychotics for challenging behaviour in adults with intellectual disability: a systematic review
2017, The Lancet PsychiatryCitation Excerpt :Intellectual disability is a lifelong condition of impaired cognitive function and deficit in adaptive skills.1 Antipsychotic medication is often prescribed to adults with intellectual disability to manage challenging behaviour in the absence of severe mental illness.2,3 Challenging behaviour is a non-specific term used to describe any behaviour that can threaten the physical safety of a person with intellectual disability or those around them, or that is likely to limit access to ordinary community facilities.4
A 3-year follow-up study on cardiovascular disease and mortality in older people with intellectual disabilities
2016, Research in Developmental DisabilitiesThe association between the Patient Protection and Affordable Care Act and healthcare affordability among US adults with intellectual disability
2023, Journal of Intellectual Disability Research